Results 191 to 200 of about 1,296,096 (233)
Some of the next articles are maybe not open access.
2009
Endogenous and synthetic cannabinoids are known for their psychotic and analgesic potency upon systemic administration. Topical cannabinoid agonists are a new modality in chronic pruritus since a couple of years. Both cannabinoid receptors CB1 and CB2 were found to be expressed on cutaneous sensory nerve fibres, mast cells, and keratinocytes.
openaire +1 more source
Endogenous and synthetic cannabinoids are known for their psychotic and analgesic potency upon systemic administration. Topical cannabinoid agonists are a new modality in chronic pruritus since a couple of years. Both cannabinoid receptors CB1 and CB2 were found to be expressed on cutaneous sensory nerve fibres, mast cells, and keratinocytes.
openaire +1 more source
Cannabinoid receptor agonists and antagonists
Expert Opinion on Therapeutic Patents, 1998Following the discovery of two distinct cannabinoid receptors (CB1 and CB2) in the early 1990s, the medicinal chemistry of cannabinoids has seen renewed interest. In the last decade, at least three entirely new chemical series were shown to bind to cannabinoid receptors: the aminoalkylindoles developed by Sterling (WIN 55212-2 analogues), the fatty ...
openaire +1 more source
The cannabinoid receptors and their interactions with synthetic cannabinoid agonists and antagonists
2002Here we describe the characteristics of the cannabinoid receptor subtypes, CB1 and CB2, and what we know of their interactions with certain ligands. CB1 and CB2 are members of the superfamily of 7 transmembrane domain (7TM) receptors that transduce intracellular signals via heterotrimeric GTP-binding proteins.
Francis Barth +9 more
openaire +2 more sources
SR141716A is an inverse agonist at the human cannabinoid CB1 receptor
European Journal of Pharmacology, 1997The effects of R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4- benzoxazin-yl]-(1-napthalenyl)methanone mesylate (WIN 55,212-2) and N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazo le-carboxamide (SR141716A) on guanosine-5'-O-(3-[35S]thio)triphosphate ([35S]GTPgammaS) binding to membranes isolated from ...
R S, Landsman +4 more
openaire +2 more sources
Synthetic Cannabinoid Receptor Agonists (SCRAs)
2022The first illicit use of cannabimimetics did not come to notice until about 2008. These substances had been evaluated in academic and pharmaceutical laboratories as potential medicines which would have some of the desirable properties of cannabis but without the unwanted psychoactive effects.
openaire +1 more source
Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and their Therapeutic Potential
Current Medicinal Chemistry, 2023Orazio Nicolotti +2 more
exaly
Fourth Generation of Synthetic Cannabinoid Receptor Agonists: A Review on the Latest Insights
Current Pharmaceutical Design, 2022Sara Malaca +2 more
exaly
Synthetic cannabinoid receptor agonists: classification and nomenclature
Clinical Toxicology, 2020S H L Thomas
exaly